Literature DB >> 22554965

Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy.

Daniel G Ezra1, Jonathan Krell, Geoffrey E Rose, Maryse Bailly, Justin Stebbing, Leandro Castellano.   

Abstract

AIMS: The pathogenesis of thyroid-associated orbitopathy (TAO) remains unclear. The aim of this study is to elucidate the gene expression profile of orbital fat from patients with active, but untreated, TAO.
METHODS: A case-control gene expression study was conducted using test samples of orbital fat from TAO patients and control orbital fat specimens; apart from drugs to control thyrotoxicosis, the TAO patients had received no treatment for orbital disease. cDNA expression analysis was performed using the Affymetrix GeneChip Human Genome U133 Plus 2.0 platform and validated using quantitative PCR.
RESULTS: The highest-ranked differentially expressed genes were dominated by IGF-1 signalling genes. These include IGF-1, IGF-1 receptor binding/signalling genes, such as SOCS3 and IRS2, and downstream signalling and transcriptional regulators, such as SGK (PDK/Akt signalling) and c-JUN. Our microarray data also demonstrate dysregulation of wingless-type MMTV (Wnt) signalling gene expression, including Wnt5a, sFRPs and DKK.
CONCLUSION: Altered Wnt signalling confirms previous array findings. Further investigation of the role of Wnt signalling in TAO pathogenesis is warranted. These data also provide the first evidence of dysregulation of IGF-1 pathway genes in TAO tissue, further strengthening the evidence for the role of IGF-1 signalling in the pathogenesis and potential treatment of TAO.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22554965      PMCID: PMC7611799          DOI: 10.1136/jclinpath-2012-200719

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  32 in total

1.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

Authors:  Rafael A Irizarry; Bridget Hobbs; Francois Collin; Yasmin D Beazer-Barclay; Kristen J Antonellis; Uwe Scherf; Terence P Speed
Journal:  Biostatistics       Date:  2003-04       Impact factor: 5.899

2.  Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor.

Authors:  Terry J Smith; Neil Hoa
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

Review 3.  Alternative wnt signaling is initiated by distinct receptors.

Authors:  Renée van Amerongen; Amanda Mikels; Roel Nusse
Journal:  Sci Signal       Date:  2008-09-02       Impact factor: 8.192

4.  IGF-1 up-regulates K+ channels via PI3-kinase, PDK1 and SGK1.

Authors:  N Gamper; S Fillon; S M Huber; Y Feng; T Kobayashi; P Cohen; F Lang
Journal:  Pflugers Arch       Date:  2001-11-14       Impact factor: 3.657

Review 5.  Immunopathogenesis of thyroid eye disease: emerging paradigms.

Authors:  Vibhavari M Naik; Milind N Naik; Robert A Goldberg; Terry J Smith; Raymond S Douglas
Journal:  Surv Ophthalmol       Date:  2010 May-Jun       Impact factor: 6.048

Review 6.  Structure and function of the type 1 insulin-like growth factor receptor.

Authors:  T E Adams; V C Epa; T P Garrett; C W Ward
Journal:  Cell Mol Life Sci       Date:  2000-07       Impact factor: 9.261

7.  Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis.

Authors:  Raymond S Douglas; Andrew G Gianoukakis; Shweta Kamat; Terry J Smith
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

8.  Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.

Authors:  Shanli Tsui; Vibha Naik; Neil Hoa; Catherine J Hwang; Nikoo F Afifiyan; Amiya Sinha Hikim; Andrew G Gianoukakis; Raymond S Douglas; Terry J Smith
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

9.  Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy.

Authors:  Seema Kumar; Michael J Coenen; Philipp E Scherer; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

10.  Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group.

Authors:  L Tallstedt; G Lundell; O Tørring; G Wallin; J G Ljunggren; H Blomgren; A Taube
Journal:  N Engl J Med       Date:  1992-06-25       Impact factor: 91.245

View more
  16 in total

1.  The Aryl Hydrocarbon Receptor and Its Ligands Inhibit Myofibroblast Formation and Activation: Implications for Thyroid Eye Disease.

Authors:  Collynn F Woeller; Elisa Roztocil; Christine L Hammond; Steven E Feldon; Richard P Phipps
Journal:  Am J Pathol       Date:  2016-11-11       Impact factor: 4.307

Review 2.  2021 update on thyroid-associated ophthalmopathy.

Authors:  E J Neag; T J Smith
Journal:  J Endocrinol Invest       Date:  2021-08-20       Impact factor: 5.467

Review 3.  Thinking inside the box: Current insights into targeting orbital tissue remodeling and inflammation in thyroid eye disease.

Authors:  Vardaan Gupta; Christine L Hammond; Elisa Roztocil; Mithra O Gonzalez; Steven E Feldon; Collynn F Woeller
Journal:  Surv Ophthalmol       Date:  2021-09-04       Impact factor: 6.197

Review 4.  Rituximab for thyroid-associated ophthalmopathy.

Authors:  Swan Kang; Shirin Hamed Azzam; Neda Minakaran; Daniel G Ezra
Journal:  Cochrane Database Syst Rev       Date:  2022-06-16

Review 5.  Molecular diagnosis: Implications for ophthalmology.

Authors:  James T Rosenbaum; Cailin H Sibley; Dongseok Choi; Christina A Harrington; Stephen R Planck
Journal:  Prog Retin Eye Res       Date:  2015-12-01       Impact factor: 21.198

6.  The Role of the Immune Response in the Pathogenesis of Thyroid Eye Disease: A Reassessment.

Authors:  James T Rosenbaum; Dongseok Choi; Amanda Wong; David J Wilson; Hans E Grossniklaus; Christina A Harrington; Roger A Dailey; John D Ng; Eric A Steele; Craig N Czyz; Jill A Foster; David Tse; Chris Alabiad; Sander Dubovy; Prashant K Parekh; Gerald J Harris; Michael Kazim; Payal J Patel; Valerie A White; Peter J Dolman; Deepak P Edward; Hind M Alkatan; Hailah Al Hussain; Dinesh Selva; R Patrick Yeatts; Bobby S Korn; Don O Kikkawa; Patrick Stauffer; Stephen R Planck
Journal:  PLoS One       Date:  2015-09-15       Impact factor: 3.240

7.  Transcriptomic Profiling of Control and Thyroid-Associated Orbitopathy (TAO) Orbital Fat and TAO Orbital Fibroblasts Undergoing Adipogenesis.

Authors:  Dong Won Kim; Kamil Taneja; Thanh Hoang; Clayton P Santiago; Timothy J McCulley; Shannath L Merbs; Nicholas R Mahoney; Seth Blackshaw; Fatemeh Rajaii
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-07-01       Impact factor: 4.799

8.  Tocilizumab for thyroid eye disease.

Authors:  Shirin Hamed Azzam; Swan Kang; Mario Salvi; Daniel G Ezra
Journal:  Cochrane Database Syst Rev       Date:  2018-11-27

Review 9.  Drug discovery in ophthalmology: past success, present challenges, and future opportunities.

Authors:  Nicholas J D Gower; Robert J Barry; Matthew R Edmunds; Lucy C Titcomb; Alastair K Denniston
Journal:  BMC Ophthalmol       Date:  2016-01-16       Impact factor: 2.209

10.  RNA-Sequencing Gene Expression Profiling of Orbital Adipose-Derived Stem Cell Population Implicate HOX Genes and WNT Signaling Dysregulation in the Pathogenesis of Thyroid-Associated Orbitopathy.

Authors:  Wensi Tao; Juan A Ayala-Haedo; Matthew G Field; Daniel Pelaez; Sara T Wester
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-12-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.